|
|
|
| Application of Yanhuanglian Injection Assisted FOLFOXIRI Chemotherapy in Treatment of Patients with Advanced Colorectal Cancer |
| FAN Lei, SONG Xiang-ni |
| People's Hospital of Tongchuan, tongchuan 727100 |
|
|
|
|
Abstract 【Objective】To explore the effects of Yanhuanglian injection assisted FOLFOXIRI chemotherapy on the immune and clinical treatment in patients with advanced colorectal cancer. 【Methods】A retrospectively randomized control study was conducted in 102 patients with advanced colorectal cancer in our hospital from March 2017 to March 2020. They were divided into the observation group ( n =51) and the control group ( n =51) according to a random number table. Patients in the control group received FOLFOXIRI chemotherapy, and patients in the observation group received Yanhuanglian injection assisted FOLFOXIRI chemotherapy. Both groups were treated for 4 chemotherapy cycles. The efficacy and quality of life improvement rate, serum angiogenesis indicators [transforming growth factor-β1 (TGF-β1), hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF)], immune function index (CD3+, CD4+, CD4+/CD8+), tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), carbohydrate antigen 125 (CA125)] levels before and after treatment were compared between the two groups. 【Results】The total effective rate and the improvement rate of quality of life after 4 cycles of chemotherapy in the observation group were 54.90% and 66.67%, respectively, which were higher than 35.29% and 41.18% in the control group ( P <0.05). Serum levels of TGF-β1, HIF-1α, VEGF, CEA, CA199, CA125, and miR-217 in the two groups after treatment for 4 cycles of chemotherapy were lower than those before treatment. And the levels in the observation group was lower than those in the control group. After treatment, serum levels of CD3+, CD4+, CD4+/CD8+ in the observation group were not statistically different from those before treatment ( P >0.05). The above indicators in the control group were lower than before treatment; and the difference was statistically significant ( P <0.05). Serum levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group after 4 cycles of chemotherapy ( P <0.05). 【Conclusion】The application of Yanhuanglian injection assisted FOLFOXIRI chemotherapy in the treatment of patients with advanced colorectal cancer can inhibit angiogenesis, reduce the expression of tumor markers, reduce immune function damage and improve efficacy and quality of life.
|
|
Received: 12 October 2020
|
|
|
|
|
|
[1] Mody K, Baldeo C, Bekaii-Saab T.Antiangiogenic therapy in colorectal cancer[J]. Cancer J, 2018,24(4):165-170.
[2] Piawah S.Targeted therapy for colorectal cancer metastases:A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer[J]. Cancer, 2019,125(23):4139-4147.
[3] 王珍,郑松,徐锡枫,等.改良FOLFOXIRI方案作为三线或三线后方案治疗晚期结直肠癌的回顾性研究[J].中国肿瘤临床,2018,45(14):735-740.
[4] 诸葛明丽,蒋伟哲,肖萍,等.壮药岩黄连研究进展[J].海峡药学,2019,31(5):31-34.
[5] 刘燕青,陈辉.健脾益气法联合含雷替曲塞化疗方案对晚期结直肠癌患者的临床疗效及免疫功能的影响[J].现代消化及介入诊疗,2019,24(7):759-763.
[6] 刘永. 利水消胀方敷脐联合紫杉醇腹腔灌注治疗消化系统癌性腹水的临床研究[D].合肥:安徽中医药大学,2019.
[7] 张伟鹏,徐元元,刘苇,等.FOLFOXIRI与SOX化疗方案治疗晚期结直肠癌的近期效果比较[J].肿瘤研究与临床,2018,30(8):548-552.
[8] 胡俊,王银华,叶斌,等.FOLFOXIRI联合Kras基因靶向治疗方案对晚期结直肠癌预后的影响[J].现代消化及介入诊疗,2019,24(2):146-149.
[9] 蔡红妃,求是.华蟾素注射液联合化疗治疗老年结直肠癌患者近期疗效观察及对患者血清肿瘤标志物和免疫功能的影响[J].中国医师进修杂志,2020,43(4):368-372.
[10] 张芝华,李淑荣,马桂勇,等.岩黄连注射液联合TACE对中晚期肝癌患者免疫功能和生活质量的影响[J].河北医药,2019,41(19):2902-2905.
[11] 余姣娇,邱志霞,刘秋燕,等.岩黄连的研究进展[J].药学研究,2018,37(6):342-345.
[12] 刘烨,高志海,安燚.结肠癌组织中转化生长因子-β1和缺氧诱导因子-1α及血管内皮生长因子的表达及临床意义[J].中国慢性病预防与控制,2019,27(5):352-355.
[13] 张俊,李晓洁.四种血清肿瘤标志物在结直肠癌患者中的诊断价值分析[J].川北医学院学报,2019,34(6):719-721.
[14] 李小妹,顾艳,杨柳.FOLFIRI联合艾迪注射液治疗晚期结直肠癌的疗效及对免疫功能的影响[J].癌症进展,2018,16(10):69-72.
[15] 唐超玲,刘平,郑华,等.岩黄连化学成分及药理作用研究进展[J].中药新药与临床药理,2018,29(1):104-109. |
|
|
|
2021, Vol. 38 
